Brain metastases occur in ~35% of HER2+ metastatic breast cancer patients. Many patients now develop brain metastases as a first site of progression with stable systemic disease and, increasingly, brain metastases contribute to patient death. We report that pazopanib, an approved inhibitor of VEGFRs, PDGFRs and c-kit, reduced brain metastatic colonization in two experimental breast cancer models overexpressing the HER2 oncogene. In vitro studies using 231-BR cells revealed an unexpected diminution of tumor ERK activation despite the presence of both Ras and B-Raf mutations; enzymatic assays confirmed a new function for pazopanib as a B-Raf inhibitor. In the 231-BR-HER2 model, reduced brain metastasis formation was accompanied by reduced pERK but no change in vessel density. The data suggest pazopanib as a candidate for brain metastasis prevention. The data also identify a new activity for this drug which may enable new rational combinations.
Introduction
The majority of cancer patients succumb to metastatic disease or the consequences of its treatment. While metastasis to any site in the body is a devastating event, the brain may represent a "final frontier". Brain metastases are ten-fold more prevalent than primary tumors of the brain (1) , concentrated in lung and breast carcinomas and melanoma. In breast cancer, brain metastases occur predominately in the HER2+ and triple negative subtypes (2) . The incidence of brain metastatic disease has increased to approximately 35% in patients with HER2+ metastatic breast cancer (3) (4) (5) (6) .
The majority of HER2+ metastatic patients experienced a brain relapse when either responding to treatment systemically or experiencing stable systemic disease, and up to 50% of deaths were due to brain disease (7) (8) (9) . Current treatments are palliative including steroids, cranial radiotherapy, and surgical resection. Brain metastases are designated an unmet medical need by the US Food and Drug Administration.
The mechanistic basis of brain metastasis has been investigated using brain tropic breast cancer cell lines. Several molecular pathways have been reported to contribute to brain metastatic potential including HER2 (10), VEGF-A (11), integrin v 3 (12) and
Stat3 (13) . We developed a quantifiable brain metastasis mouse model using a brain seeking variant of the MDA-MB-231 breast carcinoma cell line (231-BR). When injected into the left cardiac ventricle, 231-BR cells produce numerous metastases. HER2 transfectants of 231-BR produced comparable numbers of micrometastases as controls, indicating that the ability of tumor cells to arrive in the brain and complete the first few rounds of division was not affected by HER2 overexpression; however, large metastases
Results
Pazopanib inhibits human brain microvascular endothelial cell growth. To confirm the anti-angiogenic activity of pazopanib, its effect on human brain microvascular endothelial cells (HBMEC) was analyzed. The IC 50 for pazopanib for anchorage-dependent growth was 2 M and 1 M after 48 h and 72 h, respectively (Fig.   S1A ). In an in vitro tube formation assay, pazopanib disrupted 50% of the network at 1 M ( Fig. S1B and C) . Pazopanib abrogated the phosphorylation of VEGFR2 with disruption of downstream PLCγ1 (Fig. S1D ). Pazopanib also disrupted the Ras-Raf-ERK pathway through decreased phosphorylated MEK1/2 and ERK1/2 and affected the phosphorylation of 70S6K. Our findings confirmed that pazopanib targeted endothelial cells, affecting cell growth, VEGFR-induced signaling, and tube formation.
Pazopanib inhibits 231-BR breast cancer cell growth and the ERK1/2 signaling pathway. The brain-seeking derivative of human MDA-MB-231 breast cancer cells (231-BR) expresses VEGFR1 ( Fig. 1 ). We therefore hypothesized that pazopanib could also directly target tumor cells. In vitro assays were performed using vector (231-BR-vector) and HER2 transfectants (231-BR-HER2) of the 231-BR cell line. In an anchorage-dependent growth assay, the IC 50 of pazopanib was 5 M for both cell lines after 96 hours of culture ( Fig. 1A ). This dose was considered physiologically relevant because it was in the same range as the in vitro growth inhibition of lapatinib on 231-BR cells (21) . We therefore deciphered the signaling pathways disrupted by pazopanib on both 231-BR-vector and 231-BR-HER2 cell lines. VEGFR1 phosphorylation was inhibited by pazopanib at 0.5 M (Fig. 1B Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research by the phosphorylation level of its substrate, MEK1 ( Fig. 2A ). Increasing concentrations of pazopanib inhibited the phosphorylation of MEK1. As a positive control, a nonclinical Raf inhibitor inhibited MEK1 phosphorylation; as a negative control, lapatinib, a kinase pocket inhibitor of HER2 and EGFR, had no effect on phospho-MEK1. Thus, pazopanib directly targeted wild type B-Raf.
Pazopanib was then tested in an enzymatic assay using total lysate from three tumor cell lines to investigate the spectrum of its B-Raf inhibitory activity (Fig. 2B ). The 
Pazopanib prevents the brain metastatic outgrowth of the 231-BR-HER2
human breast cancer cell line. We asked if pazopanib was effective in preventing brain metastasis and investigated its mechanism of action in vivo. The 231-BR-HER2 cell line was injected in the left cardiac ventricle of nude mice and treatment with vehicle, 30 mg/kg or 100 mg/kg pazopanib started 3 days after cell injection. Mice were treated twice daily by oral gavage for 21 days. To quantify the effect of pazopanib on metastatic tumor cell colonization of the brain, the number of large metastatic lesions and micrometastases were quantified in H&E-stained brain sections (Table 1 and Fig. S2 ). A cutoff of 300 microns in a single dimension was chosen to separate large metastases from micrometastases because it is proportional to a ~5mm MRI detectable lesion in a human Pazopanib treatment had no effect on either the normal brain or the metastatic vasculature. In the normal brain, the number of blood vessels per high power field was 61.4 6.53 in the vehicle group versus 63.5 5.32 and 55.2 5.06 in the 30 mg/kg and 100 mg/kg pazopanib treated groups, respectively. The small decrease in blood vessel density with pazopanib treatment did not achieve statistical significance. In the brain metastases, the number of blood vessels was 44.2 2.30 per high power field in the vehicle treated group versus 42.2 4.36 and 46.8 4.35 in the 30 mg/kg and 100 mg/kg pazopanib treated groups, respectively. The same trend was observed for the percent of area covered by blood vessel (Fig. 4A and B ).
Pazopanib prevents the brain metastatic outgrowth of the MCF7-HER2-BR3
human breast cancer cell line. To evaluate the efficacy of pazopanib in an independent brain metastatic model, we developed a brain seeking cell line using the MCF7 breast cancer cells transfected with HER2. After three rounds of intracardiac injection, brain dissection, cell culture and re-injection into mice, the MCF7-HER2-BR3 cell line produced a single brain metastasis compressing and invading the hypothalamus and thalamus region and sometimes extending further to the Pons of the brain in approximately 70% of mice injected. S4A ). Pazopanib at low dose induced a slight increase in pERK1/2 but, at higher doses, a decrease was observed (Fig. S4B ). This trend was previously described in recent papers (26, 28) . Cell cycle analysis showed that, after 72h of vehicle treatment, 55.67% of cells were in G0/G1, 30.96% were in S phase and 13.36% are in G2/M. Five M pazopanib induced a complete cell cycle arrest in G0/G1 ( Fig. S4C ).
Using this model, mice were treated with vehicle or 100 mg/kg pazopanib, starting 3 days post-injection and extending for six weeks thereafter. MRI analysis was performed on the brains of mice on day 42 post-injection and tumor volume calculated.
Ten mice per treatment arm were randomly chosen for MRI analysis.
Four mice from the control arm had to be euthanization 5 days before the end of the experiment, compared to one mouse from the pazopanib treated arm. For the MRI analysis, seven of ten mice per experimental arm developed brain metastases. Metastasis volume for all lesions calculated and representative MRI images are shown ( Figure 5A and B and Supplemental Figure S5 ). Brain metastases were heterogeneous in size in the Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research and D). Remodeling of blood vasculature was also observed in this model. The blood vessel density was slightly decreased in the metastases compared to normal brain but did not reach statistical significance (p=0.15). However blood vessels were much more dilated in metastases: the blood vessels covered 2.00 to 2.16% of normal brain area and 6.02 to 6.46% in the metastases (both p<0.0001) (Fig. 5D ). Nevertheless, no effect of pazopanib was observed among metastases or normal brain in terms of blood vessel density (Fig. 5C ) or vessel area (Fig. 5D ). Figure 5E is representative photographs of normal brain tissues. Representative photographs of blood vessels in metastatic tissue are shown in figure 5F . The data confirm vessel remodeling in brain metastases but fail to demonstrate an anti-angiogenic effect of pazopanib. 
Discussion
We report a new activity for the multi-kinase inhibitor pazopanib, the inhibition of tumor cell B-Raf activity. B-Raf has been identified as an oncogene and B-Raf mutations are found in approximately 7% of human cancers with the highest frequency in malignant melanoma (29) (30) (31) (32) . Drugs targeting B-Raf have been reported with distinct profiles of activity against the wild type and mutated forms of B-Raf and its family members (24, (33) (34) . Our findings emanated from the observation that pazopanib inhibited the proliferation of 231-BR tumor cells directly. Pazopanib has been reported to inhibit the proliferation of lung cancer cells and multiple myeloma cells as well (35) (36) . Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research experimental brain metastasis model using the estrogen receptor+ MCF7 cell line transfected with HER2. After three rounds of brain passage, the MCF7-HER2-BR3 line produced one large brain metastasis in approximately 70% of mice 6 weeks postinjection. Pazopanib reduced the size of the brain metastases by 55% (p=0.067). More control than pazopanib treated mice were eliminated from MRI analysis as they required sacrifice before the end of the experiments; histological analyses of the brains at necropsy revealed large metastases in all mice (data not shown). Inclusion of these mice in the MRI analysis may have improved the efficacy of pazopanib over that reported. The data suggest a role for pazopanib in the prevention of HER2+ brain metastatic colonization which could be tested in the metastatic setting or in the time to the development of a new metastasis in brain metastatic patients treated with drug. Future studies will investigate rational combinations of HER2 therapeutics such as lapatinib and pazopanib for the prevention and treatment of brain metastasis. We are attempting to derive brain metastatic sublines of naturally occurring HER2+ breast cancer cell lines for these studies.
Given the multiplicity of activities of pazopanib, we attempted to determine the relative contribution of anti-angiogenesis versus Raf inhibitory activity in the experimental brain metastasis assays. The role of angiogenesis in metastasis has been controversial generally and in the brain (11, (14) (15) (39) (40) (41) (42) . In the 231-BR-HER2 model, brain metastasis development per se resulted in vascular remodeling. Lower vessel densities and higher percentages of brain area covered by vessels corresponded to fewer but dilated vessels, in agreement with previous reports (14) . In the MCF7-HER2-BR3 model, higher percentages of brain area covered by vessels were also observed. However, Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research no effect of pazopanib at either dose tested was found on these parameters in both models. It remains possible that other aspects of vascular permeability and remodeling may be affected in the brain, and that pazopanib may exert anti-angiogenic responses in other organ sites of metastasis.
In contrast, a significant decrease in pMEK1/2 and pERK1/2 staining was observed in pazopanib treated 231-BR-HER2 brain metastases, confirming the in vivo modulation of Raf activity. For technical reasons, pMEK1/2 and pERK1/2 staining could not be performed on the MCF7-HER2-BR3 model. Indeed, each brain was bisected along the saggittal plane and each hemisphere fixed differently for the various analyses presented herein. Unfortunately, it turned out that the metastases favored one hemisphere, leaving inadequate amounts of metastatic tissue for the pMEK1/2 and pERK1/2 staining.
Characterization of the signaling pathways altered by pazopanib in MCF7-HER2 mammary fat pad xenografts in vivo is ongoing; results to date showed a significant decrease in pERK1/2 after pazopanib treatement 7 . The data indicate that the recently discovered B-Raf inhibitory activity of pazopanib is active in vivo, and may be of preventive significance. These data may permit new clinical trials to be developed and rational combinations tested.
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